The Effect of Multiple Subcutaneous Doses of Risankizumab on the Single Dose Pharmacokinetics of Cytochrome P450 Substrates (Caffeine, Warfarin, Omeprazole, Metoprolol and Midazolam) Administered Orally in an Open-label, One-sequence Trial in Patients With Plaque Psoriasis With or Without Concomitant Psoriatic Arthritis

Trial Profile

The Effect of Multiple Subcutaneous Doses of Risankizumab on the Single Dose Pharmacokinetics of Cytochrome P450 Substrates (Caffeine, Warfarin, Omeprazole, Metoprolol and Midazolam) Administered Orally in an Open-label, One-sequence Trial in Patients With Plaque Psoriasis With or Without Concomitant Psoriatic Arthritis

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs Risankizumab (Primary) ; Caffeine; Metoprolol; Midazolam; Omeprazole; Warfarin
  • Indications Plaque psoriasis; Psoriatic arthritis
  • Focus Pharmacokinetics
  • Sponsors AbbVie; Boehringer Ingelheim
  • Most Recent Events

    • 17 Apr 2017 Planned primary completion date changed from 1 May 2017 to 1 Jun 2017.
    • 13 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 29 Sep 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top